8-K: SelectQuote Reports Strong Fiscal Year 2024 Results, Announces Securitization Plan

SelectQuote's fiscal year 2024 saw significant revenue growth and improved profitability, with the company also announcing a plan to securitize approximately $100 million in commission receivables.

Summary

• SelectQuote reported its fourth quarter and full fiscal year 2024 results, showing a revenue of $307.2 million for the quarter and $1.3 billion for the year.
• The company's net loss for the quarter was $31.0 million, and $34.1 million for the full year.
• Adjusted EBITDA was $14.4 million for the quarter and $117.0 million for the year.
• The company's revenue and Adjusted EBITDA outperformed the midpoint of their original forecast by 17% and 26%, respectively.
• SelectRx membership grew by 68% year-over-year, reaching approximately 82,000 members.
• The company has signed a non-binding letter of intent to complete an initial commissions receivable securitization of approximately $100 million.
• Fiscal year 2025 revenue is expected to be in the range of $1.4 billion to $1.5 billion, with a net loss between $42 million and $6 million, and Adjusted EBITDA between $90 million and $120 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and improved profitability, but there are some concerns about the net loss and the expected decline in Senior MA volume. The planned securitization is a positive step, but the company still faces some risks.

Positives

• SelectQuote's revenue and Adjusted EBITDA exceeded the midpoint of their original forecast by 17% and 26%, respectively.
• The company has achieved 10 consecutive quarters of outperformance versus internal expectations.
• The Senior segment achieved a strong 25% Adjusted EBITDA margin for the full year.
• The Healthcare Services segment achieved its 5th straight quarter of profitability.
• SelectRx membership grew significantly, increasing by 68% year-over-year.
• The company is planning a $100 million securitization of commission receivables to improve its balance sheet.
• The company's revenue to customer acquisition cost multiple increased to 4.5x from 4.1x in the previous year.
• The company's operating cash flow and free cash flow were positive during fiscal year 2024.

Negatives

• The company reported a net loss of $31.0 million for the fourth quarter and $34.1 million for the full year.
• The Healthcare Services segment's Adjusted EBITDA margin was only 1% for the fourth quarter.
• The number of approved Medicare Advantage policies decreased by 3% in the fourth quarter compared to the same period last year.
• The number of approved Medicare Supplement policies decreased by 29% in the fourth quarter compared to the same period last year.
• The Life segment's Adjusted EBITDA decreased by 13% for the full year.
• The company expects a 10-15% decline in Senior MA volume for 2025 due to capital constraints.

Risks

• The company relies on a limited number of insurance carrier partners, and the termination of these relationships could negatively impact the business.
• Changes in health insurance products, regulations, and commission structures could affect the company's revenue and profitability.
• Competition from other brokers, online brokers, and insurance carriers selling directly to consumers poses a risk.
• The company's dependence on lead providers and the ability to convert leads into sales is crucial for success.
• The company's existing and future indebtedness and compliance with debt covenants are ongoing risks.
• The company's ability to maintain compliance with NYSE listing standards is a risk.
• The company faces risks related to cybersecurity breaches and the protection of consumer information.
• The company's pharmacy business faces risks related to manufacturing, supply chain, and regulatory changes.
• A shift in commission structure from a large insurance carrier partner will limit capital availability during the Medicare Advantage selling season.

Future Outlook

SelectQuote expects fiscal year 2025 revenue to be between $1.4 billion and $1.5 billion, with a net loss between $42 million and $6 million, and Adjusted EBITDA between $90 million and $120 million. The company anticipates a 10-15% decline in Senior MA volume due to capital constraints, but expects strong growth in Healthcare Services.

Management Comments

• SelectQuote Chief Executive Officer, Tim Danker, commented, 2024 was another successful and strong year for SelectQuote across both Senior Medicare Advantage distribution and our Healthcare Services business, driven by SelectRx.
• Mr. Danker continued, SelectQuotes unique healthcare information platform remains best positioned as a value creation conduit, efficiently connecting a large and growing population of Americans in need of coverage and care with the best providers, based on each of their distinct personal needs.

Industry Context

The results reflect the ongoing demand for Medicare Advantage plans and the growing importance of healthcare services, particularly pharmacy services, within the senior market. The company's focus on profitability and cash efficiency aligns with broader industry trends emphasizing sustainable growth. The shift in commission structure from a large insurance carrier partner highlights the dynamic nature of the insurance market and the need for companies to adapt to changing conditions.

Comparison to Industry Standards

• SelectQuote's 25% Adjusted EBITDA margin in the Senior segment is strong compared to other insurance brokers, though specific benchmarks vary widely.
• The 68% growth in SelectRx members is significant, indicating a strong market position in the pharmacy services sector, though direct comparisons to other pharmacy benefit managers are difficult without more specific data.
• The company's revenue to customer acquisition cost multiple of 4.5x is a positive indicator of efficient marketing spend, but this metric is not always directly comparable across different business models.
• The planned securitization of commission receivables is a common strategy in the insurance industry to improve liquidity and balance sheet management, similar to practices used by other large insurance brokers.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved profitability positively, but may be concerned about the net loss and the expected decline in Senior MA volume.
• Employees may be encouraged by the company's growth and profitability, but may also be aware of the challenges ahead.
• Customers will benefit from the company's continued focus on providing unbiased comparisons and personalized solutions.
• Suppliers and creditors may view the company's financial performance and securitization plan as positive indicators of its stability.

Next Steps

• The company plans to complete the initial commissions receivable securitization of approximately $100 million.
• The company will continue to focus on growing its Healthcare Services business, particularly SelectRx.
• The company will aim to deliver on its 20%+ Adjusted EBITDA margin target within the Senior business.

Key Dates

Keywords

SelectQuote, Insurance, Medicare Advantage, Healthcare Services, SelectRx, Adjusted EBITDA, Commissions, Securitization, Financial Results, Revenue, Net Loss